UC HEALTH LINE: New Survey Can Help Predict Hip Fracture Risk in Women
CINCINNATIA team of 11 researchers across the country have developed a diagnostic model that may help identify postmenopausal women at risk for hip fractures, even before they show signs of osteoporosis.
The researchers, including Nelson Watts, MD, director of the University of Cincinnatis Bone Health and Osteoporosis Center, evaluated clinical risk factors associated with hip fractures using data from more than 94,000 women (aged 50-79) of various ethnic backgrounds participating in the Womens Health Initiative, an ongoing national health study.
Detailed in the Nov. 28, 2007, issue of The Journal of the American Medical Association (JAMA), the team identified 11 factors that were predictive of hip fractures in five years:
- Age
- Weight
- Height
- Race/ethnicity
- General health
- Physical activity
- Personal history of a fracture after age 55
- Parent history of a fracture
- Current smoking
- Current corticosteroid use
- Treated diabetes
Bone density scanning is the best test we have for identifying hip fracture risk, says Watts. However, we need other ways to identify risk because more than half of hip fractures actually occur in those whose bone density score doesnt meet the criterion for osteoporosis.
Watts says knowing a patients risk for hip fractures allows her and her doctor to develop a treatment plan thats right for her, including medical intervention and lifestyle changes.
Ive been asking patients about many of these risk factors for years, says Watts. But now we have scientific evidence of their importance as well as the combination of factors for hip fracture risk.
Osteoporosis is a silent disease, says
The JAMA study was led by John Robbins, MD, of the University of California at Davis.
Tags
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.
Heavy social media use linked to depression
August 31, 2026
U.S. News and World Report, Yahoo! News, MSN, USA Today and other national media highlight a new study by the University of Cincinnati and Northwestern University that found a correlation between heavy social media use and depression in adults.